Britain's prostate cancer screening plan is a start. But too many men remain outside it.

By Ed Parkin RN—Medical Director and Head of Propositions, Klarity

In March, the UK National Screening Committee recommended a targeted national prostate cancer screening programme for the first time, a genuine milestone after years of debate. But look more closely and it becomes considerably smaller. The programme offers PSA testing every two years to men aged 45 to 61 with a pathogenic BRCA2 gene variant and a family history of breast, ovarian, pancreatic or prostate cancer. Most other men remain outside a nationally organised screening pathway.

The Committee concluded that, for much of the wider population, current evidence suggests screening would cause more harm than good, an honest reflection of a difficult clinical problem rather than a criticism of the NHS. PSA testing is imperfect. An elevated result does not necessarily mean cancer, while some cancers occur without a markedly raised PSA. Abnormal results can lead to further investigation and anxiety, while screening can identify cancers that would never have caused harm during a man's lifetime.

But being cautious about population-wide screening and leaving most men without an organised pathway are two different things. Prostate cancer is the most commonly diagnosed cancer in men in the UK and more than 12,000 men die from it every year. A policy designed for one narrow genetic subgroup does not reflect the scale of the problem.

Contemporary testing rates specifically for men aged 40 to 65 are not well established, but are likely to be relatively low in any given year, rising with age and skewed towards symptomatic or self-initiated testing. The new programme will do little to change that at scale, since it only invites men with a confirmed BRCA2 variant and qualifying family history, aged 45 to 61. The Institute of Cancer Research estimates that up to 32,000 men in the UK aged 45 to 69 could carry a BRCA variant. Many may not know their status because genetic testing has historically focused more heavily on women, meaning some men who could benefit from the new pathway may not know they are eligible.

The conversation now needs to go beyond whether we should screen and ask how we identify the men most likely to benefit.

Prostate cancer is not exclusively an older man's disease

Age remains the most important risk factor for prostate cancer, and the disease is uncommon before 50, though not impossible.

Sir Chris Hoy was 47 when he was diagnosed with stage 4 prostate cancer, after seeking advice for shoulder pain that turned out to be cancer spread from his prostate to his bones. His diagnosis was shocking partly because he appeared to represent the opposite of the person many imagine when they think about serious illness, i.e. young, fit and one of Britain's most successful Olympians.

His experience should not be used to suggest that every younger man needs screening. It should remind us that age and outward health cannot provide complete reassurance.

Black men and men with a family history of prostate cancer have a higher underlying risk, with discussions about PSA testing often recommended from age 45. A confirmed BRCA2 variant is only one part of this broader risk picture. A more personalised approach would weigh age alongside ethnicity, family history, genetics and symptoms, giving men clear information so they can make an informed choice.

PSA works best as part of a pathway

PSA has important limitations as a standalone test. For men who undergo testing, the result should be considered as part of a clinically governed pathway that takes account of individual risk, symptoms and repeat testing where appropriate, with MRI and specialist referral according to clinical guidance. The objective is not simply to maximise cancer detection, but to identify clinically significant disease early enough to improve outcomes while minimising overdiagnosis and unnecessary investigation.

What about the men outside the programme?

Consider a man whose father or brother had prostate cancer but who has no known BRCA2 variant. Or a Black man at substantially greater lifetime risk, but with no family history and no known BRCA2 variant. Neither is included in the new national programme.

They are not without options; men can discuss their individual risk and PSA testing with a healthcare professional. What they lack is a consistent, organised pathway that proactively identifies risk and provides access to appropriate follow-up.

There is also an important evidence gap where we still need better data on finding aggressive cancers earlier without exposing large numbers of men to unnecessary investigation. The new programme should be seen as a starting point, not the end of the debate.

Bridging the gap

The NHS has taken an important first step, but a substantial gap remains for men outside the new programme. This is where organisations outside national screening can play a complementary role, starting with the most basic barrier - access to the test itself. At Klarity, our focus today is on making PSA testing easier to access for men who want to understand their risk, so that decision doesn't have to wait for an organised NHS pathway that, for most men, doesn't yet exist. The next step, for the field as a whole, is building out what comes after a result, so that men and their clinicians know what a raised PSA should lead to next.

Sir Chris Hoy's experience reminds us that prostate cancer does not always fit the profile we expect. Earlier identification of risk will not prevent every late diagnosis, but a more personalised approach can give more men the opportunity to make informed decisions and act before symptoms appear. Britain has made an important start; the next challenge is ensuring that men whose risk does not fit neatly within the new programme are not forgotten.